The role of NAD+ metabolism and its modulation of mitochondria in aging and disease
Chini, C. C. S., Zeidler, J. D., Kashyap, S., Warner, G. & Chini, E. N. Evolving concepts in NAD+ metabolism. Cell Metab. 33, 1076–1087 (2021).
Google Scholar
Judge, A. & Dodd, M. S. Metabolism. Essays Biochem. 64, 607–647 (2020).
Google Scholar
Kalyanaraman, B. et al. A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: therapeutic targeting of tumor mitochondria with lipophilic cationic compounds. Redox Biol. 14, 316–327 (2018).
Google Scholar
Xie, N. et al. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct. Target. Ther. 5, 227 (2020).
Google Scholar
Ying, W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid. Redox Signal. 10, 179–206 (2008).
Google Scholar
Dasovich, M. & Leung, A. K. L. PARPs and ADP-ribosylation: Deciphering the complexity with molecular tools. Mol. Cell 83, 1552–1572 (2023).
Google Scholar
Zeidler, J. D. et al. The CD38 glycohydrolase and the NAD sink: implications for pathological conditions. Am. J. Physiol. Cell Physiol. 322, C521–C545 (2022).
Google Scholar
Encyclopedia of Food and Health (Elsevier, 2016).
Brody, T. Nutritional Biochemistry (Academic Press, San Diego, 1999).
Fernández-Vizarra, E., Enríquez, J. A., Pérez-Martos, A., Montoya, J. & Fernández-Silva, P. Tissue-specific differences in mitochondrial activity and biogenesis. Mitochondrion 11, 207–213 (2011).
Google Scholar
Mori, V. et al. Metabolic profiling of alternative NAD biosynthetic routes in mouse tissues. PLoS ONE 9, e113939 (2014).
Google Scholar
McLaughlin, K. L. et al. Novel approach to quantify mitochondrial content and intrinsic bioenergetic efficiency across organs. Sci. Rep. 10, 17599 (2020).
Google Scholar
Sorrentino, V., Menzies, K. J. & Auwerx, J. Repairing mitochondrial dysfunction in disease. Annu. Rev. Pharmacol. Toxicol. 58, 353–389 (2018).
Google Scholar
Stein, L. R. & Imai, S. The dynamic regulation of NAD metabolism in mitochondria. Trends Endocrinol. Metab. 23, 420–428 (2012).
Google Scholar
Pittelli, M. et al. Pharmacological effects of exogenous NAD on mitochondrial bioenergetics, DNA repair, and apoptosis. Mol. Pharm. 80, 1136–1146 (2011).
Google Scholar
Fiers, W., Beyaert, R., Declercq, W. & Vandenabeele, P. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 18, 7719–7730 (1999).
Google Scholar
Juan, C. A., Pérez de la Lastra, J. M., Plou, F. J. & Pérez-Lebeña, E. The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. Int. J. Mol. Sci. 22, 4642 (2021).
Google Scholar
Ma, K. et al. Mitophagy, mitochondrial homeostasis, and cell fate. Front. Cell Dev. Biol. 8, 467 (2020).
Google Scholar
Shpilka, T. & Haynes, C. M. The mitochondrial UPR: mechanisms, physiological functions and implications in ageing. Nat. Rev. Mol. Cell Biol. 19, 109–120 (2018).
Google Scholar
Combs, G. F. The Vitamins: Fundamental Aspects in Nutrition and Health (Elsevier/AP, Amsterdam, 2012).
Hove-Jensen, B. et al. Phosphoribosyl diphosphate (PRPP): biosynthesis, enzymology, utilization, and metabolic significance. Microbiol Mol. Biol. Rev. 81, e00040–16 (2017).
Google Scholar
Hara, N., Yamada, K., Shibata, T., Osago, H. & Tsuchiya, M. Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLoS ONE 6, e22781 (2011).
Google Scholar
Pinson, B., Ceschin, J., Saint-Marc, C. & Daignan-Fornier, B. Dual control of NAD+ synthesis by purine metabolites in yeast. eLife 8, e43808 (2019).
Google Scholar
Tsui, M. et al. Purine nucleoside phosphorylase deficiency induces p53-mediated intrinsic apoptosis in human induced pluripotent stem cell-derived neurons. Sci. Rep. 12, 9084 (2022).
Google Scholar
Kropotov, A. et al. Purine nucleoside phosphorylase controls nicotinamide riboside metabolism in mammalian cells. J. Biol. Chem. 298, 102615 (2022).
Google Scholar
Bender, D. A. & Olufunwa, R. Utilization of tryptophan, nicotinamide and nicotinic acid as precursors for nicotinamide nucleotide synthesis in isolated rat liver cells. Br. J. Nutr. 59, 279–287 (1988).
Google Scholar
Bieganowski, P. & Brenner, C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 117, 495–502 (2004).
Google Scholar
Preiss, J. & Handler, P. Biosynthesis of diphosphopyridine nucleotide. I. Identification of intermediates. J. Biol. Chem. 233, 488–492 (1958).
Google Scholar
Preiss, J. & Handler, P. Biosynthesis of diphosphopyridine nucleotide. II. Enzymatic aspects. J. Biol. Chem. 233, 493–500 (1958).
Google Scholar
Zhang, X. et al. Structural characterization of a human cytosolic NMN/NaMN adenylyltransferase and implication in human NAD biosynthesis. J. Biol. Chem. 278, 13503–13511 (2003).
Google Scholar
Efimov, I. et al. Heme-containing dioxygenases. In Advances in Inorganic Chemistry Vol. 64 33–51 (Elsevier, 2012).
Han, Q., Robinson, H. & Li, J. Biochemical identification and crystal structure of kynurenine formamidase from Drosophila melanogaster. Biochem. J. 446, 253–260 (2012).
Google Scholar
Revollo, J. R., Grimm, A. A. & Imai, S. I. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 279, 50754–50763 (2004).
Google Scholar
Lau, C., Niere, M. & Ziegler, M. The NMN/NaMN adenylyltransferase (NMNAT) protein family. Front. Biosci. Landmark Ed. 14, 410–431 (2009).
Google Scholar
Zapata-Pérez, R. et al. Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice. FASEB J. 35, e21456 (2021).
Google Scholar
Yang, Y., Zhang, N., Zhang, G. & Sauve, A. A. NRH salvage and conversion to NAD+ requires NRH kinase activity by adenosine kinase. Nat. Metab. 2, 364–379 (2020).
Google Scholar
Orlandi, I., Alberghina, L. & Vai, M. Nicotinamide, nicotinamide riboside and nicotinic acid-emerging roles in replicative and chronological aging in yeast. Biomolecules 10, 604 (2020).
Google Scholar
Belenky, P., Christensen, K. C., Gazzaniga, F., Pletnev, A. A. & Brenner, C. Nicotinamide riboside and nicotinic acid riboside salvage in fungi and mammals. Quantitative basis for Urh1 and purine nucleoside phosphorylase function in NAD+ metabolism. J. Biol. Chem. 284, 158–164 (2009).
Google Scholar
Liu, L. et al. Quantitative analysis of NAD synthesis-breakdown fluxes. Cell Metab. 27, 1067–1080.e5 (2018).
Google Scholar
Katsyuba, E., Romani, M., Hofer, D. & Auwerx, J. NAD+ homeostasis in health and disease. Nat. Metab. 2, 9–31 (2020).
Google Scholar
Wagner, S., Manickam, R., Brotto, M. & Tipparaju, S. M. NAD+ centric mechanisms and molecular determinants of skeletal muscle disease and aging. Mol. Cell Biochem. 477, 1829–1848 (2022).
Google Scholar
Sonntag, T. et al. Nicotinamide riboside kinases regulate skeletal muscle fiber-type specification and are rate-limiting for metabolic adaptations during regeneration. Front. Cell Dev. Biol. 10, 1049653 (2022).
Google Scholar
Revollo, J. R. et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 6, 363–375 (2007).
Google Scholar
Lundt, S. & Ding, S. NAD+ metabolism and diseases with motor dysfunction. Genes12, 1776 (2021).
Google Scholar
Wen, F. et al. Drug discovery targeting nicotinamide phosphoribosyltransferase (NAMPT): updated progress and perspectives. Bioorg. Med. Chem. 99, 117595 (2024).
Google Scholar
Yoshida, M. et al. Extracellular vesicle-contained eNAMPT delays aging and extends lifespan in mice. Cell Metab. 30, 329–342.e5 (2019).
Google Scholar
Covarrubias, A. J., Perrone, R., Grozio, A. & Verdin, E. NAD+ metabolism and its roles in cellular processes during ageing. Nat. Rev. Mol. Cell Biol. 22, 119–141 (2021).
Google Scholar
Nikiforov, A., Dölle, C., Niere, M. & Ziegler, M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J. Biol. Chem. 286, 21767–21778 (2011).
Google Scholar
Canto, C. NAD+ precursors: a questionable redundancy. Metabolites 12, 630 (2022).
Google Scholar
Camacho-Pereira, J. et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 23, 1127–1139 (2016).
Google Scholar
Chini, E. N., Chini, C. C. S., Espindola Netto, J. M., de Oliveira, G. C. & van Schooten, W. The pharmacology of CD38/NADase: an emerging target in cancer and diseases of aging. Trends Pharmacol. Sci. 39, 424–436 (2018).
Google Scholar
Shi, B. et al. Targeting CD38-dependent NAD+ metabolism to mitigate multiple organ fibrosis. iScience 24, 101902 (2021).
Google Scholar
Hopkins, E. L., Gu, W., Kobe, B. & Coleman, M. P. A novel NAD signaling mechanism in axon degeneration and its relationship to innate immunity. Front. Mol. Biosci. 8, 703532 (2021).
Google Scholar
Loreto, A., Antoniou, C., Merlini, E., Gilley, J. & Coleman, M. P. NMN: The NAD precursor at the intersection between axon degeneration and anti-ageing therapies. Neurosci. Res. 197, 18–24 (2023).
Google Scholar
Bitterman, K. J., Anderson, R. M., Cohen, H. Y., Latorre-Esteves, M. & Sinclair, D. A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem. 277, 45099–45107 (2002).
Google Scholar
Domínguez-Gómez, G. et al. Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin. Oncol. Rep. 33, 721–728 (2015).
Google Scholar
Roberti, A., Fernández, A. F. & Fraga, M. F. Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation. Mol. Metab. 45, 101165 (2021).
Google Scholar
Migaud, M. E., Ziegler, M. & Baur, J. A. Regulation of and challenges in targeting NAD+ metabolism. Nat. Rev. Mol. Cell Biol. 25, 822–840 (2024).
Google Scholar
Gazzaniga, F., Stebbins, R., Chang, S. Z., McPeek, M. A. & Brenner, C. Microbial NAD metabolism: lessons from comparative genomics. Microbiol. Mol. Biol. Rev. 73, 529–541 (2009). Table of Contents.
Google Scholar
Magnúsdóttir, S., Ravcheev, D., de Crécy-Lagard, V. & Thiele, I. Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes. Front. Genet. 6, 148 (2015).
Google Scholar
Lozada-Fernández, V. V. et al. Nicotinamide riboside-conditioned microbiota deflects high-fat diet-induced weight gain in mice. mSystems 7, e0023021 (2022).
Google Scholar
Yu, X. et al. Effect of nicotinamide riboside on lipid metabolism and gut microflora-bile acid axis in alcohol-exposed mice. Food Sci. Nutr. 9, 429–440 (2021).
Google Scholar
Peluso, A. A. et al. Oral supplementation of nicotinamide riboside alters intestinal microbial composition in rats and mice, but not humans. NPJ Aging 9, 7 (2023).
Google Scholar
Bruzzone, S., Guida, L., Zocchi, E., Franco, L. & De Flora, A. Connexin 43 hemi channels mediate Ca2+-regulated transmembrane NAD+ fluxes in intact cells. FASEB J. 15, 10–12 (2001).
Google Scholar
Wei, W., Graeff, R. & Yue, J. Roles and mechanisms of the CD38/cyclic adenosine diphosphate ribose/Ca(2+) signaling pathway. World J. Biol. Chem. 5, 58–67 (2014).
Google Scholar
Grant, R. et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 h intravenous infusion of NAD. Front. Aging Neurosci. 11, 257 (2019).
Google Scholar
Grozio, A. et al. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells. J. Biol. Chem. 288, 25938–25949 (2013).
Google Scholar
Ratajczak, J. et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat. Commun. 7, 13103 (2016).
Google Scholar
Sauve, A. A. et al. Triple-Isotope Tracing for Pathway Discernment of NMN-Induced NAD+ Biosynthesis in Whole Mice. Int. J. Mol. Sci. 24, 11114 (2023).
Google Scholar
Grozio, A. et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat. Metab. 1, 47–57 (2019).
Google Scholar
Kanai, Y. et al. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J. Biol. Chem. 273, 23629–23632 (1998).
Google Scholar
Pillai, S. M. & Meredith, D. SLC36A4 (hPAT4) is a high affinity amino acid transporter when expressed in Xenopus laevis oocytes. J. Biol. Chem. 286, 2455–2460 (2011).
Google Scholar
Chen, M. et al. SLC29A1 and SLC29A2 are human nicotinamide cell membrane transporters. Nat. Commun. 16, 1181 (2025).
Google Scholar
Ohkubo, M., Ohta, K., Inoue, K. & Yuasa, H. Nicotinate uptake by two kinetically distinct Na÷-dependent carrier-mediated transport systems in the rat small intestine. Drug Metab. Pharmacokinet. 27, 255–262 (2012).
Google Scholar
Bahn, A. et al. Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J. Biol. Chem. 283, 16332–16341 (2008).
Google Scholar
Alano, C. C. et al. Differences among cell types in NAD(+) compartmentalization: a comparison of neurons, astrocytes, and cardiac myocytes. J. Neurosci. Res. 85, 3378–3385 (2007).
Google Scholar
Cambronne, X. A. et al. Biosensor reveals multiple sources for mitochondrial NAD+. Science 352, 1474–1477 (2016).
Google Scholar
Kory, N. et al. MCART1/SLC25A51 is required for mitochondrial NAD transport. Sci. Adv. 6, eabe5310 (2020).
Google Scholar
Luongo, T. S. et al. SLC25A51 is a mammalian mitochondrial NAD+ transporter. Nature 588, 174–179 (2020).
Google Scholar
Berger, F., Lau, C., Dahlmann, M. & Ziegler, M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J. Biol. Chem. 280, 36334–36341 (2005).
Google Scholar
Yamamoto, M. et al. Nmnat3 is dispensable in mitochondrial NAD level maintenance in vivo. PLoS ONE 11, e0147037 (2016).
Google Scholar
Zhu, Y., Liu, J., Park, J., Rai, P. & Zhai, R. G. Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies. Pharmacol. Ther. 200, 27–41 (2019).
Google Scholar
Fletcher, R. S. et al. Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells. Mol. Metab. 6, 819–832 (2017).
Google Scholar
Svoboda, P. et al. Nuclear transport of nicotinamide phosphoribosyltransferase is cell cycle-dependent in mammalian cells, and its inhibition slows cell growth. J. Biol. Chem. 294, 8676–8689 (2019).
Google Scholar
Chen, L. et al. Quantitative dynamics of intracellular NMN by genetically encoded biosensor. Biosens. Bioelectron. 267, 116842 (2025).
Google Scholar
Michishita, E., Park, J. Y., Burneskis, J. M., Barrett, J. C. & Horikawa, I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell 16, 4623–4635 (2005).
Google Scholar
Nolfi-Donegan, D., Braganza, A. & Shiva, S. Mitochondrial electron transport chain: Oxidative phosphorylation, oxidant production, and methods of measurement. Redox Biol. 37, 101674 (2020).
Google Scholar
Gorman, G. S. et al. Mitochondrial diseases. Nat. Rev. Dis. Prim. 2, 16080 (2016).
Google Scholar
Yusri, K., Kumar, S., Fong, S., Gruber, J. & Sorrentino, V. Towards healthy longevity: comprehensive insights from molecular targets and biomarkers to biological clocks. Int. J. Mol. Sci. 25, 6793 (2024).
Google Scholar
Alano, C. C. et al. NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J. Neurosci. 30, 2967–2978 (2010).
Google Scholar
Yang, H. et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130, 1095–1107 (2007).
Google Scholar
Titov, D. V. et al. Complementation of mitochondrial electron transport chain by manipulation of the NAD+/NADH ratio. Science 352, 231–235 (2016).
Google Scholar
Liu, Y., Hu, L., Ma, T., Yang, J. & Ding, J. Insights into the inhibitory mechanisms of NADH on the αγ heterodimer of human NAD-dependent isocitrate dehydrogenase. Sci. Rep. 8, 3146 (2018).
Google Scholar
Cuenoud, B. et al. Brain NAD is associated with ATP energy production and membrane phospholipid turnover in humans. Front. Aging Neurosci. 12, 609517 (2020).
Google Scholar
Jang, S., Kang, H. T. & Hwang, E. S. Nicotinamide-induced mitophagy: event mediated by high NAD+/NADH ratio and SIRT1 protein activation. J. Biol. Chem. 287, 19304–19314 (2012).
Google Scholar
Yuan, X. et al. NAD+/NADH redox alterations reconfigure metabolism and rejuvenate senescent human mesenchymal stem cells in vitro. Commun. Biol. 3, 774 (2020).
Google Scholar
Wang, H. et al. Nicotinamide mononucleotide supplementation improves mitochondrial dysfunction and rescues cellular senescence by NAD+/Sirt3 pathway in mesenchymal stem cells. Int. J. Mol. Sci. 23, 14739 (2022).
Google Scholar
Meng, H. et al. SIRT3 regulation of mitochondrial quality control in neurodegenerative diseases. Front. Aging Neurosci. 11, 313 (2019).
Google Scholar
Huang, L. et al. Effect of Sirt3 on retinal pigment epithelial cells in high glucose through Foxo3a/ PINK1-Parkin pathway mediated mitophagy. Exp. Eye Res. 218, 109015 (2022).
Google Scholar
Tseng, A. H. H., Shieh, S.-S. & Wang, D. L. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic. Biol. Med. 63, 222–234 (2013).
Google Scholar
Mohrin, M. et al. Stem cell aging. A mitochondrial UPR-mediated metabolic checkpoint regulates hematopoietic stem cell aging. Science 347, 1374–1377 (2015).
Google Scholar
Wang, C.-L. et al. The mitochondrial unfolded protein response regulates hippocampal neural stem cell aging. Cell Metab. 35, 996–1008.e7 (2023).
Google Scholar
Zhou, Y., Wang, S., Li, Y., Yu, S. & Zhao, Y. SIRT1/PGC-1α signaling promotes mitochondrial functional recovery and reduces apoptosis after intracerebral hemorrhage in rats. Front. Mol. Neurosci. 10, 443 (2017).
Google Scholar
Lemos, V. et al. The NAD+-dependent deacetylase SIRT2 attenuates oxidative stress and mitochondrial dysfunction and improves insulin sensitivity in hepatocytes. Hum. Mol. Genet. 26, 4105–4117 (2017).
Google Scholar
Cha, Y. et al. SIRT2 regulates mitochondrial dynamics and reprogramming via MEK1-ERK-DRP1 and AKT1-DRP1 axes. Cell Rep. 37, 110155 (2021).
Google Scholar
Fasano, C., Disciglio, V., Bertora, S., Lepore Signorile, M. & Simone, C. FOXO3a from the nucleus to the mitochondria: a round trip in cellular stress response. Cells 8, 1110 (2019).
Google Scholar
Sundaresan, N. R. et al. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Invest. 119, 2758–2771 (2009).
Google Scholar
Zhang, H. et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science 352, 1436–1443 (2016).
Google Scholar
Mouchiroud, L. et al. The NAD(+)/Sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 154, 430–441 (2013).
Google Scholar
Cantó, C. et al. The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15, 838–847 (2012).
Google Scholar
Fang, E. F. et al. NAD+ replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 24, 566–581 (2016).
Google Scholar
Fang, E. F. et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease. Nat. Neurosci. 22, 401–412 (2019).
Google Scholar
Klimova, N., Long, A. & Kristian, T. Nicotinamide mononucleotide alters mitochondrial dynamics by SIRT3-dependent mechanism in male mice. J. Neurosci. Res. 97, 975–990 (2019).
Google Scholar
Romani, M. et al. NAD+ boosting reduces age-associated amyloidosis and restores mitochondrial homeostasis in muscle. Cell Rep. 34, 108660 (2021).
Google Scholar
Song, S. B. et al. Modulation of mitochondrial membrane potential and ROS generation by nicotinamide in a manner independent of SIRT1 and mitophagy. Mol. Cells 40, 503–514 (2017).
Google Scholar
Braıdy, N. Intravenous NAD+ effectively increased the NAD metabolome, reduced oxidative stress and inflammation, and increased expression of longevity genes safely in elderly humans. J. Cell. Neurosci. Oxid. Stress 10, 779–779 (2018).
Google Scholar
Gibson, S. B., Mestayer, R., Berg, J., Grant, R. & Dyess, G. Intravenous administration of nicotinamide adenine dinucleotide improves cognitive performance in human subjects: implications for clinical populations. Arch. Phys. Med. Rehabil. 102, e42 (2021).
Google Scholar
Munk, S. H. N. et al. NAD+ regulates nucleotide metabolism and genomic DNA replication. Nat. Cell Biol. 25, 1774–1786 (2023).
Google Scholar
Radenkovic, D., Reason & Verdin, E. Clinical evidence for targeting NAD therapeutically. Pharmaceuticals 13, 247 (2020).
Google Scholar
Song, Q. et al. The safety and antiaging effects of nicotinamide mononucleotide in human clinical trials: an update. Adv. Nutr. 14, 1416–1435 (2023).
Google Scholar
Damgaard, M. V. & Treebak, J. T. What is really known about the effects of nicotinamide riboside supplementation in humans. Sci. Adv. 9, eadi4862 (2023).
Google Scholar
Henderson, J. D., Quigley, S. N. Z., Chachra, S. S., Conlon, N. & Ford, D. The use of a systems approach to increase NAD+ in human participants. NPJ Aging 10, 7 (2024).
Google Scholar
Bodor, E. T. & Offermanns, S. Nicotinic acid: an old drug with a promising future. Br. J. Pharmacol. 153, S68–S75 (2008).
Google Scholar
Membrez, M. et al. Trigonelline is an NAD+ precursor that improves muscle function during ageing and is reduced in human sarcopenia. Nat. Metab. 6, 433–447 (2024).
Google Scholar
Giroud-Gerbetant, J. et al. A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor. Mol. Metab. 30, 192–202 (2019).
Google Scholar
Chellappa, K. et al. NAD precursors cycle between host tissues and the gut microbiome. Cell Metab. 34, 1947–1959.e5 (2022).
Google Scholar
Yaku, K. et al. BST1 regulates nicotinamide riboside metabolism via its glycohydrolase and base-exchange activities. Nat. Commun. 12, 6767 (2021).
Google Scholar
Yang, Y., Mohammed, F. S., Zhang, N. & Sauve, A. A. Dihydronicotinamide riboside is a potent NAD+ concentration enhancer in vitro and in vivo. J. Biol. Chem. 294, 9295–9307 (2019).
Google Scholar
Liu, Y. et al. Reduced nicotinamide mononucleotide (NMNH) potently enhances NAD+ and suppresses glycolysis, the TCA cycle, and cell growth. J. Proteome Res. 20, 2596–2606 (2021).
Google Scholar
Aktar, S., Ferdousi, F., Kondo, S., Kagawa, T. & Isoda, H. Transcriptomics and biochemical evidence of trigonelline ameliorating learning and memory decline in the senescence-accelerated mouse prone 8 (SAMP8) model by suppressing proinflammatory cytokines and elevating neurotransmitter release. GeroScience (2023).
Farid, M. M., Yang, X., Kuboyama, T. & Tohda, C. Trigonelline recovers memory function in Alzheimer’s disease model mice: evidence of brain penetration and target molecule. Sci. Rep. 10, 16424 (2020).
Google Scholar
Sauve, A. A. & Schramm, V. L. Mechanism-based inhibitors of CD38: a mammalian cyclic ADP-ribose synthetase. Biochemistry 41, 8455–8463 (2002).
Google Scholar
Sauve, A. A., Munshi, C., Lee, H. C. & Schramm, V. L. The reaction mechanism for CD38. A single intermediate is responsible for cyclization, hydrolysis, and base-exchange chemistries. Biochemistry 37, 13239–13249 (1998).
Google Scholar
Hogan, K. A., Chini, C. C. S. & Chini, E. N. The multi-faceted ecto-enzyme CD38: Roles In Immunomodulation, Cancer, Aging, and Metabolic Diseases. Front. Immunol. 10, 1187 (2019).
Google Scholar
Aksoy, P., White, T. A., Thompson, M. & Chini, E. N. Regulation of intracellular levels of NAD: a novel role for CD38. Biochem. Biophys. Res. Commun. 345, 1386–1392 (2006).
Google Scholar
Piedra-Quintero, Z. L., Wilson, Z., Nava, P. & Guerau-de-Arellano, M. CD38: An Immunomodulatory Molecule In Inflammation And Autoimmunity. Front. Immunol. 11, 597959 (2020).
Google Scholar
Liu, Q. et al. Covalent and noncovalent intermediates of an NAD utilizing enzyme, human CD38. Chem. Biol. 15, 1068–1078 (2008).
Google Scholar
Tarragó, M. G. et al. A Potent And Specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD+ decline. Cell Metab. 27, 1081–1095.e10 (2018).
Google Scholar
Peclat, T. R. et al. CD38 inhibitor 78c increases mice lifespan and healthspan in a model of chronological aging. Aging Cell 21, e13589 (2022).
Google Scholar
Kellenberger, E., Kuhn, I., Schuber, F. & Muller-Steffner, H. Flavonoids as inhibitors of human CD38. Bioorg. Med. Chem. Lett. 21, 3939–3942 (2011).
Google Scholar
Wang, H., Li, S., Zhang, G., Wu, H. & Chang, X. Potential therapeutic effects of cyanidin-3-O-glucoside on rheumatoid arthritis by relieving inhibition of CD38+ NK cells on Treg cell differentiation. Arthritis Res. Ther. 21, 220 (2019).
Google Scholar
Tang, D., Chen, K., Huang, L. & Li, J. Pharmacokinetic properties and drug interactions of apigenin, a natural flavone. Expert Opin. Drug Metab. Toxicol. 13, 323–330 (2017).
Google Scholar
Escande, C. et al. Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes 62, 1084–1093 (2013).
Google Scholar
Ogura, Y., Kitada, M., Xu, J., Monno, I. & Koya, D. CD38 inhibition by apigenin ameliorates mitochondrial oxidative stress through restoration of the intracellular NAD+/NADH ratio and Sirt3 activity in renal tubular cells in diabetic rats. Aging 12, 11325–11336(2020).
Google Scholar
Covarrubias, A. J. et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nat. Metab. 2, 1265–1283 (2020).
Google Scholar
Adamia, S. et al. Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. Leukemia 36, 1088–1101 (2022).
Google Scholar
Gozzetti, A. et al. Anti CD38 monoclonal antibodies for multiple myeloma treatment. Hum. Vaccin Immunother. 18, 2052658 (2022).
Google Scholar
Sanchez, L., Wang, Y., Siegel, D. S. & Wang, M. L. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J. Hematol. Oncol. 9, 51 (2016).
Google Scholar
van de Donk, N. W. C. J. et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol. Rev. 270, 95–112 (2016).
Google Scholar
Abadier, M., Estevam, J., Berg, D. & Fedyk, E. R. Mezagitamab induces immunomodulatory effect in patients with relapsed/refractory multiple myeloma (RRMM). Blood 136, 9–9 (2020).
Google Scholar
Dwivedi, S., Rendón-Huerta, E. P., Ortiz-Navarrete, V. & Montaño, L. F. CD38 and regulation of the immune response cells in cancer. J. Oncol. 2021, 6630295 (2021).
Google Scholar
Raab, M. S. et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet Haematol. 7, e381–e394 (2020).
Google Scholar
Romano, A. et al. Mechanisms of action of the new antibodies in use in multiple myeloma. Front. Oncol. 11, 684561 (2021).
Google Scholar
Franssen, L. E., Stege, C. A. M., Zweegman, S., van de Donk, N. W. C. J. & Nijhof, I. S. Resistance mechanisms towards CD38-Directed antibody therapy in multiple myeloma. J. Clin. Med. 9, 1195 (2020).
Google Scholar
Jiao, Y. et al. CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers. Expert Opin. Investig. Drugs 29, 1295–1308 (2020).
Google Scholar
Ugamraj, H. S. et al. TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity. MAbs 14, 2095949 (2022).
Google Scholar
Qian, M. et al. Boosting ATM activity alleviates aging and extends lifespan in a mouse model of progeria. eLife 7, e34836 (2018).
Google Scholar
Hu, Y. et al. Aβ promotes CD38 expression in senescent microglia in Alzheimer’s disease. Biol. Res. 55, 10 (2022).
Google Scholar
Zha, S., Li, Z., Cao, Q., Wang, F. & Liu, F. PARP1 inhibitor (PJ34) improves the function of aging-induced endothelial progenitor cells by preserving intracellular NAD+ levels and increasing SIRT1 activity. Stem Cell Res. Ther. 9, 224 (2018).
Google Scholar
Min, A. & Im, S.-A. PARP inhibitors as therapeutics: beyond modulation of PARylation. Cancers12, 394 (2020).
Google Scholar
Singh, N., Pay, S. L., Bhandare, S. B., Arimpur, U. & Motea, E. A. Therapeutic strategies and biomarkers to modulate PARP activity for targeted cancer therapy. Cancers12, 972 (2020).
Google Scholar
Paldino, E. et al. Modulation of inflammasome and pyroptosis by olaparib, a PARP-1 inhibitor, in the R6/2 mouse model of Huntington’s disease. Cells 9, 2286 (2020).
Google Scholar
Kovacs, K. et al. PARP inhibitor protects against chronic hypoxia/reoxygenation-induced retinal injury by regulation of MAPKs, HIF1α, Nrf2, and NFκB. Invest. Ophthalmol. Vis. Sci. 60, 1478–1490 (2019).
Google Scholar
Gariani, K. et al. Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease. J. Hepatol. 66, 132–141 (2017).
Google Scholar
Bridges, K. A. et al. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget 5, 5076–5086 (2014).
Google Scholar
Mogol, A. N., Kaminsky, A. Z., Dutton, D. J. & Madak Erdogan, Z. Targeting NAD+ metabolism: preclinical insights into potential cancer therapy strategies. Endocrinology 165, bqae043 (2024).
Google Scholar
Jones, P., Wilcoxen, K., Rowley, M. & Toniatti, C. Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. J. Med. Chem. 58, 3302–3314 (2015).
Google Scholar
Martin-Oliva, D. et al. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res. 66, 5744–5756 (2006).
Google Scholar
Wang, G. et al. PARP-1 inhibitor, DPQ, attenuates LPS-induced acute lung injury through inhibiting NF-κB-mediated inflammatory response. PLoS ONE 8, e79757 (2013).
Google Scholar
Damiani, R. M. et al. Influence of PARP-1 inhibition in the cardiotoxicity of the topoisomerase 2 inhibitors doxorubicin and mitoxantrone. Toxicol. Vitr. 52, 203–213 (2018).
Google Scholar
Caldini, R. et al. Low doses of 3-aminobenzamide, a poly(ADP-ribose) polymerase inhibitor, stimulate angiogenesis by regulating expression of urokinase type plasminogen activator and matrix metalloprotease 2. Vasc. Cell 3, 12 (2011).
Google Scholar
Woodhouse, B. C. & Dianov, G. L. Poly ADP-ribose polymerase-1: an international molecule of mystery. DNA Repair7, 1077–1086 (2008).
Google Scholar
Lo, E. H., Bosque-Hamilton, P. & Meng, W. Inhibition of poly(ADP-ribose) polymerase: reduction of ischemic injury and attenuation of N-methyl-D-aspartate-induced neurotransmitter dysregulation. Stroke 29, 830–836 (1998).
Google Scholar
Liaudet, L. et al. Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences. Br. J. Pharmacol. 133, 1424–1430 (2001).
Google Scholar
Krishnan Muthaiah, V. P., Kaliyappan, K. & Mahajan, S. D. Poly ADP-ribose polymerase-1 inhibition by 3-aminobenzamide recuperates HEI-OC1 auditory hair cells from blast overpressure-induced cell death. Front. Cell Dev. Biol. 11, 1047308 (2023).
Google Scholar
Ohmoto, A. & Yachida, S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther. 10, 5195–5208 (2017).
Google Scholar
Kaci, F. N. & Daglioglu, C. 3-Aminobenzamide-linked multifunctional nanoparticles enhances anticancer activity of low-dose cisplatin chemotherapy in lung adenocarcinoma. J. Drug Deliv. Sci. Technol. 100, 106038 (2024).
Google Scholar
Chung, S. et al. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch. Biochem. Biophys. 501, 79–90 (2010).
Google Scholar
Iside, C., Scafuro, M., Nebbioso, A. & Altucci, L. SIRT1 activation by natural phytochemicals: an overview. Front. Pharmacol. 11, 1225 (2020).
Google Scholar
Łanoszka, K. & Vlčková, N. Natural Sirtuin1 activators and atherosclerosis: an overview. Curr. Atheroscler. Rep. 25, 979–994 (2023).
Google Scholar
Kim, J. E. et al. Mitochondrial SIRT3 as a protective factor against cyclosporine A-induced nephrotoxicity. Sci. Rep. 14, 10143 (2024).
Google Scholar
Trinh, D., Al Halabi, L., Brar, H., Kametani, M. & Nash, J. E. The role of SIRT3 in homeostasis and cellular health. Front. Cell Neurosci. 18, 1434459 (2024).
Google Scholar
Harris, P. S., Gomez, J. D., Backos, D. S. & Fritz, K. S. Characterizing Sirtuin 3 deacetylase affinity for aldehyde dehydrogenase 2. Chem. Res. Toxicol. 30, 785–793 (2017).
Google Scholar
Li, Y. et al. Role of SIRT3 in neurological diseases and rehabilitation training. Metab. Brain Dis. 38, 69–89 (2023).
Google Scholar
Ma, S., Fan, L. & Cao, F. Combating cellular senescence by sirtuins: implications for atherosclerosis. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 1822–1830 (2019).
Google Scholar
Troelsen, K. S. et al. Mitochondria-targeted inhibitors of the human SIRT3 lysine deacetylase. RSC Chem. Biol. 2, 627–635 (2021).
Google Scholar
Pillai, V. B. et al. Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. Oncotarget 8, 34082–34098 (2017).
Google Scholar
Peng, F. et al. 2-APQC, a small-molecule activator of Sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis. Signal Transduct. Target Ther. 9, 133 (2024).
Google Scholar
Lee, J. H., Yun, C. W., Hur, J. & Lee, S. H. Fucoidan rescues p-cresol-induced cellular senescence in mesenchymal stem cells via FAK-Akt-TWIST axis. Mar. Drugs 16, 121 (2018).
Google Scholar
Lin, Y. et al. The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations. Cancer Cell Int. 20, 154 (2020).
Google Scholar
Li, J.-J. et al. Nicotinamide N-methyltransferase (NNMT): a new hope for treating aging and age-related conditions. Metabolites 14, 343 (2024).
Google Scholar
Rahnasto-Rilla, M. K. et al. The identification of a SIRT6 activator from brown algae Fucus distichus. Mar. Drugs 15, 190 (2017).
Google Scholar
Zhang, L. et al. Fucoidans are novel senotherapeutics that enhance sirt6 and DNA repair activity. Innov. Aging 6, 732–732 (2022).
Google Scholar
Kim, S. et al. Sirtuin 7 inhibitor attenuates colonic mucosal immune activation in mice-potential therapeutic target in inflammatory bowel disease. Biomedicines 10, 2693 (2022).
Google Scholar
Sun, W.-D. et al. Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome. Front. Pharmacol. 15, 1410479 (2024).
Google Scholar
Liu, M. et al. Serum N(1)-methylnicotinamide is associated with obesity and diabetes in Chinese. J. Clin. Endocrinol. Metab. 100, 3112–3117 (2015).
Google Scholar
Ruf, S. et al. Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. Sci. Rep. 12, 15440 (2022).
Google Scholar
Kannt, A. et al. A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. Sci. Rep. 8, 3660 (2018).
Google Scholar
Chen, D. et al. Novel propargyl-linked bisubstrate analogues as tight-binding inhibitors for nicotinamide N-methyltransferase. J. Med. Chem. 62, 10783–10797 (2019).
Google Scholar
Policarpo, R. L. et al. High-affinity alkynyl bisubstrate inhibitors of nicotinamide N-methyltransferase (NNMT). J. Med. Chem. 62, 9837–9873 (2019).
Google Scholar
Meng, Y., Iyamu, I. D., Ahmed, N. A. M. & Huang, R. Comparative analysis of two NNMT bisubstrate inhibitors through chemoproteomic studies: uncovering the role of unconventional SAM analogue moiety for improved selectivity. ACS Chem. Biol. 19, 89–100 (2024).
Google Scholar
Lee, H.-Y. et al. Covalent inhibitors of nicotinamide N-methyltransferase (NNMT) provide evidence for target engagement challenges in situ. Bioorg. Med. Chem. Lett. 28, 2682–2687 (2018).
Google Scholar
Neelakantan, H. et al. Selective and membrane-permeablesmall molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 147, 141–152 (2018).
Google Scholar
Neelakantan, H. et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem. Pharmacol. 163, 481–492 (2019).
Google Scholar
Dimet-Wiley, A. L. et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Sci. Rep. 14, 15554 (2024).
Google Scholar
Ahmed-Belkacem, R., Debart, F. & Vasseur, J. Bisubstrate strategies to target methyltransferases. Eur. J. Org. Chem. 2022, e202101481 (2022).
Google Scholar
Gao, Y., Martin, N. I. & Van Haren, M. J. Nicotinamide N-methyl transferase (NNMT): an emerging therapeutic target. Drug Discov. Today 26, 2699–2706 (2021).
Google Scholar
Sampson, C. M. et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Sci. Rep. 11, 5637 (2021).
Google Scholar
Xu, Q. et al. Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment. Cancer Cell Int. 22, 242 (2022).
Google Scholar
Zhu, Y. et al. From rate-limiting enzyme to therapeutic target: the promise of NAMPT in neurodegenerative diseases. Front. Pharmacol. 13, 920113 (2022).
Google Scholar
Garten, A. et al. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat. Rev. Endocrinol. 11, 535–546 (2015).
Google Scholar
van der Veer, E. et al. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J. Biol. Chem. 282, 10841–10845 (2007).
Google Scholar
Song, J. et al. Nicotinamide phosphoribosyltransferase is required for the calorie restriction-mediated improvements in oxidative stress, mitochondrial biogenesis, and metabolic adaptation. J. Gerontol. A Biol. Sci. Med. Sci. 69, 44–57 (2014).
Google Scholar
Wei, Y., Xiang, H. & Zhang, W. Review of various NAMPT inhibitors for the treatment of cancer. Front. Pharmacol. 13, 970553 (2022).
Google Scholar
Xu, T.-Y. et al. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase. Sci. Rep. 5, 10043 (2015).
Google Scholar
Zhang, S.-L. et al. Crystal structure-based comparison of two NAMPT inhibitors. Acta Pharm. Sin. 39, 294–301 (2018).
Google Scholar
Ghanem, M. S. et al. Identification of NAPRT inhibitors with anti-cancer properties by in silico drug discovery. Pharmaceuticals 15, 848 (2022).
Google Scholar
Parisotto, M. et al. The NAMPT inhibitor FK866 increases metformin sensitivity in pancreatic cancer cells. Cancers14, 5597 (2022).
Google Scholar
Zeng, M. et al. Nicotinamide phosphoribosyltransferase inhibitor ameliorates mouse aging-induced cognitive impairment. J. Cereb. Blood Flow. Metab. 41, 2510–2523 (2021).
Google Scholar
Holen, K., Saltz, L. B., Hollywood, E., Burk, K. & Hanauske, A.-R. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest. N. Drugs 26, 45–51 (2008).
Google Scholar
Akiu, M. et al. Discovery of DS68702229 as a potent, orally available NAMPT (nicotinamide phosphoribosyltransferase) activator. Chem. Pharm. Bull.69, 1110–1122 (2021).
Google Scholar
Pinkerton, A. B. et al. Optimization of a urea-containing series of nicotinamide phosphoribosyltransferase (NAMPT) activators. Bioorg. Med. Chem. Lett. 41, 128007 (2021).
Google Scholar
Tang, S. et al. Chemistry-led investigations into the mode of action of NAMPT activators, resulting in the discovery of non-pyridyl class NAMPT activators. Acta Pharm. Sin. B 13, 709–721 (2023).
Google Scholar
Yao, H. et al. Discovery of small-molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and their preclinical neuroprotective activity. Cell Res. 32, 570–584 (2022).
Google Scholar
Hong, W., Mo, F., Zhang, Z., Huang, M. & Wei, X. Nicotinamide mononucleotide: a promising molecule for therapy of diverse diseases by targeting NAD+ metabolism. Front. Cell Dev. Biol. 8, 246 (2020).
Google Scholar
Liang, J. et al. Impact of NAD+ metabolism on ovarian aging. Immun. Ageing 20, 70 (2023).
Google Scholar
Kim, M. et al. Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates chemotherapy-induced peripheral neuropathy. Theranostics 13, 5075–5098 (2023).
Google Scholar
Olesen, U. H., Thougaard, A. V., Jensen, P. B. & Sehested, M. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol. Cancer Ther. 9, 1609–1617 (2010).
Google Scholar
Piacente, F. et al. Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors, and DNA repair. Cancer Res. 77, 3857–3869 (2017).
Google Scholar
Franco, J. et al. Structure-based identification and biological characterization of new NAPRT inhibitors. Pharmaceuticals 15, 855 (2022).
Google Scholar
Baldassarri, C. et al. Properly substituted benzimidazoles as a new promising class of nicotinate phosphoribosyltransferase (NAPRT) modulators. Pharmaceuticals 16, 189 (2023).
Google Scholar
Sporny, M. et al. Structural basis for SARM1 inhibition and activation under energetic stress. eLife 9, e62021 (2020).
Google Scholar
Chen, J. & Li, H. Characterization of novel SARM1 inhibitors for the treatment of chemotherapy-induced peripheral neuropathy. Biomedicines 12, 2123 (2024).
Google Scholar
Yoshino, J. ACMSD: a novel target for modulating NAD+ homeostasis. Trends Endocrinol. Metab. 30, 229–232 (2019).
Google Scholar
Katsyuba, E. et al. De novo NAD+ synthesis enhances mitochondrial function and improves health. Nature 563, 354–359 (2018).
Google Scholar
Cianci, M. et al. Structural Basis of Human Dimeric α-Amino-β-Carboxymuconate-ε-Semialdehyde Decarboxylase Inhibition With TES-1025. Front Mol Biosci. 9, 834700 (2022).
Google Scholar
Yang, Y. et al. Diflunisal derivatives as modulators of ACMS decarboxylase targeting the tryptophan-kynurenine pathway. J. Med. Chem. 64, 797–811 (2021).
Google Scholar
Balakrishnan, K. et al. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood 116, 886–892 (2010).
Google Scholar
Dummer, R. et al. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Ann. Oncol. 25, 1807–1812 (2014).
Google Scholar
Feuz, M. B., Meyer-Ficca, M. L. & Meyer, R. G. Beyond pellagra-research models and strategies addressing the enduring clinical relevance of NAD deficiency in aging and disease. Cells 12, 500 (2023).
Google Scholar
Fang, E. F. et al. NAD+ in aging: molecular mechanisms and translational implications. Trends Mol. Med. 23, 899–916 (2017).
Google Scholar
Gong, B. et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer’s mouse models. Neurobiol. Aging 34, 1581–1588 (2013).
Google Scholar
Sorrentino, V. et al. Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity. Nature 552, 187–193 (2017).
Google Scholar
Pirinen, E. et al. Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metab. 31, 1078–1090.e5 (2020).
Google Scholar
Ferrell, M. et al. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nat. Med. 30, 424–434 (2024).
Google Scholar
Orr, M. E. et al. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. Geroscience 46, 665–682 (2024).
Google Scholar
Schmeisser, K. et al. Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. Nat. Chem. Biol. 9, 693–700 (2013).
Google Scholar
Beltrà, M. et al. NAD+ repletion with niacin counteracts cancer cachexia. Nat. Commun. 14, 1849 (2023).
Google Scholar
Migliavacca, E. et al. Mitochondrial oxidative capacity and NAD+ biosynthesis are reduced in human sarcopenia across ethnicities. Nat. Commun. 10, 5808 (2019).
Google Scholar
Hiona, A. & Leeuwenburgh, C. The role of mitochondrial DNA mutations in aging and sarcopenia: implications for the mitochondrial vicious cycle theory of aging. Exp. Gerontol. 43, 24–33 (2008).
Google Scholar
Askanas, V. & Engel, W. K. Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau. Presse Med. 40, e219–e235 (2011).
Google Scholar
Joshi, P. R. et al. Functional relevance of mitochondrial abnormalities in sporadic inclusion body myositis. J. Clin. Neurosci. 21, 1959–1963 (2014).
Google Scholar
Aguennouz, M. et al. Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy. Neurobiol. Aging 32, 2190–2197 (2011).
Google Scholar
Ryu, D. et al. NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation. Sci. Transl. Med. 8, 361ra139 (2016).
Google Scholar
Frederick, D. W. et al. Loss of NAD homeostasis leads to progressive and reversible degeneration of skeletal muscle. Cell Metab. 24, 269–282 (2016).
Google Scholar
Das, A. et al. Impairment of an endothelial NAD+-H2S signaling network is a reversible cause of vascular aging. Cell 173, 74–89.e20 (2018).
Google Scholar
Pirinen, E. et al. Pharmacological inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab. 19, 1034–1041 (2014).
Google Scholar
Argilés, J. M., Busquets, S., Stemmler, B. & López-Soriano, F. J. Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer 14, 754–762 (2014).
Google Scholar
Park, J. M., Han, Y. M., Lee, H. J., Park, Y. J. & Hahm, K. B. Nicotinamide riboside vitamin B3 mitigated C26 adenocarcinoma-induced cancer cachexia. Front. Pharmacol. 12, 665493 (2021).
Google Scholar
Campelj, D. G. et al. The paradoxical effect of PARP inhibitor BGP-15 on irinotecan-induced cachexia and skeletal muscle dysfunction. Cancers12, 3810 (2020).
Google Scholar
Sorensen, J. C. et al. BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Front. Pharmacol. 8, 137 (2017).
Google Scholar
Basse, A. L. et al. Nampt controls skeletal muscle development by maintaining Ca2+ homeostasis and mitochondrial integrity. Mol. Metab. 53, 101271 (2021).
Google Scholar
Kim, H.-J., Jung, D.-W. & Williams, D. R. Age is just a number: progress and obstacles in the discovery of new candidate drugs for sarcopenia. Cells 12, 2608 (2023).
Google Scholar
Tsai, S.-Y. Lost in translation: challenges of current pharmacotherapy for sarcopenia. Trends Mol. Med. 30, 1047–1060 (2024).
Google Scholar
Duan, D., Goemans, N., Takeda, S., Mercuri, E. & Aartsma-Rus, A. Duchenne muscular dystrophy. Nat. Rev. Dis. Prim. 7, 13 (2021).
Google Scholar
Cardoso, D., Barthélémy, I., Blot, S. & Muchir, A. Replenishing NAD+ content reduces aspects of striated muscle disease in a dog model of Duchenne muscular dystrophy. Skelet. Muscle 13, 20 (2023).
Google Scholar
Frederick, D. W. et al. Complementary NAD+ replacement strategies fail to functionally protect dystrophin-deficient muscle. Skelet. Muscle 10, 30 (2020).
Google Scholar
Amjad, S. et al. Role of NAD+ in regulating cellular and metabolic signaling pathways. Mol. Metab. 49, 101195 (2021).
Google Scholar
Bartman, S., Coppotelli, G. & Ross, J. M. Mitochondrial dysfunction: a key player in brain aging and diseases. Curr. Issues Mol. Biol. 46, 1987–2026 (2024).
Google Scholar
Lautrup, S., Sinclair, D. A., Mattson, M. P. & Fang, E. F. NAD+ in brain aging and neurodegenerative disorders. Cell Metab. 30, 630–655 (2019).
Google Scholar
Wang, X. et al. NAD+ in Alzheimer’s disease: molecular mechanisms and systematic therapeutic evidence obtained in vivo. Front. Cell Dev. Biol. 9, 668491 (2021).
Google Scholar
Yu, M., Sporns, O. & Saykin, A. J. The human connectome in Alzheimer disease – relationship to biomarkers and genetics. Nat. Rev. Neurol. 17, 545–563 (2021).
Google Scholar
Yao, Z., Yang, W., Gao, Z. & Jia, P. Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease. Neurosci. Lett. 647, 133–140 (2017).
Google Scholar
Blacher, E. et al. Alzheimer’s disease pathology is attenuated in a CD38-deficient mouse model. Ann. Neurol. 78, 88–103 (2015).
Google Scholar
Maggiore, A. et al. Neuroprotective effects of PARP inhibitors in Drosophila models of Alzheimer’s disease. Cells 11, 1284 (2022).
Google Scholar
Fathi, M. et al. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease: a systematic Review and meta-analysis. Front. Immunol. 13, 997240 (2022).
Google Scholar
Gabrawy, M. M. et al. Dual treatment with kynurenine pathway inhibitors and NAD+ precursors synergistically extends life span in Drosophila. Aging Cell 23, e14102 (2024).
Google Scholar
Schöndorf, D. C. et al. The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson’s disease. Cell Rep. 23, 2976–2988 (2018).
Google Scholar
Flønes, I. H. et al. Mitochondrial complex I deficiency stratifies idiopathic Parkinson’s disease. Nat. Commun. 15, 3631 (2024).
Google Scholar
González-Rodríguez, P. et al. Disruption of mitochondrial complex I induces progressive Parkinsonism. Nature 599, 650–656 (2021).
Google Scholar
Jia, H. et al. High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson’s disease. J. Neurosci. Res. 86, 2083–2090 (2008).
Google Scholar
Dölle, C. et al. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nat. Commun. 7, 13548 (2016).
Google Scholar
Lehmann, S., Costa, A. C., Celardo, I., Loh, S. H. Y. & Martins, L. M. Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson’s disease. Cell Death Dis. 7, e2166 (2016).
Google Scholar
Lehmann, S., Loh, S. H. Y. & Martins, L. M. Enhancing NAD+ salvage metabolism is neuroprotective in a PINK1 model of Parkinson’s disease. Biol. Open 6, 141–147 (2017).
Google Scholar
Caito, S. W. & Aschner, M. NAD+ Supplementation attenuates methylmercury dopaminergic and mitochondrial toxicity in Caenorhabditis elegans. Toxicol. Sci. 151, 139–149 (2016).
Google Scholar
Shan, C. et al. Protective effects of β- nicotinamide adenine dinucleotide against motor deficits and dopaminergic neuronal damage in a mouse model of Parkinson’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 94, 109670 (2019).
Google Scholar
Turconi, G. et al. Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson’s disease. Heliyon 10, e34355 (2024).
Google Scholar
Yang, B. et al. NAD+ supplementation prevents STING-induced senescence in ataxia telangiectasia by improving mitophagy. Aging Cell 20, e13329 (2021).
Google Scholar
Hughes, R. O. et al. Small molecule SARM1 inhibitors recapitulate the SARM1-/- phenotype and allow recovery of a metastable pool of axons fated to degenerate. Cell Rep. 34, 108588 (2021).
Google Scholar
Alexandris, A. S. et al. Protective effects of NAMPT or MAPK inhibitors and NaR on Wallerian degeneration of mammalian axons. Neurobiol. Dis. 171, 105808 (2022).
Google Scholar
Takaso, Y. et al. Deletion of CD38 and supplementation of NAD+ attenuate axon degeneration in a mouse facial nerve axotomy model. Sci. Rep. 10, 17795 (2020).
Google Scholar
Chanvillard, L., Tammaro, A. & Sorrentino, V. NAD+ metabolism and interventions in premature renal aging and chronic kidney disease. Cells 12, 21 (2022).
Google Scholar
Cohen, J. J. Relationship between energy requirements for Na+ reabsorption and other renal functions. Kidney Int. 29, 32–40 (1986).
Google Scholar
van der Rijt, S., Leemans, J. C., Florquin, S., Houtkooper, R. H. & Tammaro, A. Immunometabolic rewiring of tubular epithelial cells in kidney disease. Nat. Rev. Nephrol. 18, 588–603 (2022).
Google Scholar
Takahashi, R. et al. The significance of NAD + metabolites and nicotinamide N-methyltransferase in chronic kidney disease. Sci. Rep. 12, 1–19 (2022).
Google Scholar
Guan, Y. et al. Nicotinamide mononucleotide, an NAD+ precursor, rescues age-associated susceptibility to AKI in a sirtuin 1-dependent manner. J. Am. Soc. Nephrol. 28, 2337–2352 (2017).
Google Scholar
Yasuda, I. et al. Pre-emptive short-term nicotinamide mononucleotide treatment in a mouse model of diabetic nephropathy. J. Am. Soc. Nephrol.32, 1355–1370 (2021).
Google Scholar
Cho, K., Kim, H., Rodriguez-Iturbe, B. & Vaziri, N. D. Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure. Am. J. Physiol. Ren. Physiol. 297, F106–F113 (2009).
Google Scholar
Zhen, X. et al. Nicotinamide supplementation attenuates renal interstitial fibrosis via boosting the activity of sirtuins. Kidney Dis.7, 186–199 (2021).
Google Scholar
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L. & Tomlinson, J. W. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management. Endocr. Rev. 41, bnz009 (2020).
Google Scholar
Liu, Y. J. et al. ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH. J. Hepatol. 82, 174–188 (2025).
Google Scholar
Koltai, E. et al. Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats. Mech. Ageing Dev. 131, 21–28 (2010).
Google Scholar
Barth, P. G. et al. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. J. Neurol. Sci. 62, 327–355 (1983).
Google Scholar
Damschroder, D. et al. Stimulating the sir2-spargel axis rescues exercise capacity and mitochondrial respiration in a Drosophila model of Barth syndrome. Dis. Model Mech. 15, dmm049279 (2022).
Google Scholar
Ji, J. et al. NAD supplementation improves mitochondrial performance of cardiolipin mutants. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1867, 159094 (2022).
Google Scholar
Zhang, H., Zhang, Y., Zhang, J. & Jia, D. Exercise alleviates cardiovascular diseases by improving mitochondrial homeostasis. J. Am. Heart Assoc. 13, e036555 (2024).
Google Scholar
Caldwell, C. C., Petzinger, G. M., Jakowec, M. W. & Cadenas, E. Treadmill exercise rescues mitochondrial function and motor behavior in the CAG140 knock-in mouse model of Huntington’s disease. Chem. Biol. Interact. 315, 108907 (2020).
Google Scholar
Hokari, F. et al. Muscle contractile activity regulates Sirt3 protein expression in rat skeletal muscles. J. Appl. Physiol.109, 332–340 (2010).
Google Scholar
Cantó, C. et al. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab. 11, 213–219 (2010).
Google Scholar
Dollerup, O. L. et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am. J. Clin. Nutr. 108, 343–353 (2018).
Google Scholar
Airhart, S. E. et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS ONE 12, e0186459 (2017).
Google Scholar
Lapatto, H. A. K. et al. Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study. Sci. Adv. 9, eadd5163 (2023).
Google Scholar
Berven, H. et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease. Nat. Commun. 14, 7793 (2023).
Google Scholar
Elhassan, Y. S. et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 28, 1717–1728.e6 (2019).
Google Scholar
Ahmadi, A. et al. Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease. JCI Insight 8, e167274 (2023).
Google Scholar
Dollerup, O. L. et al. Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men. J. Physiol. 598, 731–754 (2020).
Google Scholar
Zhou, B. et al. Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure. J. Clin. Invest. 130, 6054–6063 (2020).
Google Scholar
Wang, D. D. et al. Safety and tolerability of nicotinamide riboside in heart failure with reduced ejection fraction. JACC Basic Transl. Sci. 7, 1183–1196 (2022).
Google Scholar
Brakedal, B. et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metab. 34, 396–407.e6 (2022).
Google Scholar
Presterud, R. et al. Long-term nicotinamide riboside use improves coordination and eye movements in ataxia telangiectasia. Mov. Disord. 39, 360–369 (2024).
Google Scholar
Connell, N. et al. NAD+-precursor supplementation with L-tryptophan, nicotinic acid, and nicotinamide does not affect mitochondrial function or skeletal muscle function in physically compromised older adults. J. Nutr. 151, 2917–2931 (2021).
Google Scholar
Kuerec, A. H. et al. Towards personalized nicotinamide mononucleotide (NMN) supplementation: nicotinamide adenine dinucleotide (NAD) concentration. Mech. Ageing Dev. 218, 111917 (2024).
Google Scholar
Yi, L. et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience 45, 29–43 (2023).
Google Scholar
Yoshino, M. et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 372, 1224–1229 (2021).
Google Scholar
Igarashi, M. et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging 8, 5 (2022).
Google Scholar
Walzik, D. et al. Acute exercise boosts NAD+ metabolism of human peripheral blood mononuclear cells. Brain Behav. Immun. 123, 1011–1023 (2025).
Google Scholar
de Guia, R. M. et al. Aerobic and resistance exercise training reverses age-dependent decline in NAD+ salvage capacity in human skeletal muscle. Physiol. Rep. 7, e14139 (2019).
Google Scholar
Olszanecka-Glinianowicz, M. et al. Relationship between circulating visfatin/NAMPT, nutritional status and insulin resistance in an elderly population – results from the PolSenior substudy. Metabolism 63, 1409–1418 (2014).
Google Scholar
Lamb, D. A. et al. Resistance training increases muscle NAD+ and NADH concentrations as well as NAMPT protein levels and global sirtuin activity in middle-aged, overweight, untrained individuals. Aging12, 9447–9460 (2020).
Google Scholar
Costford, S. R. et al. Skeletal muscle NAMPT is induced by exercise in humans. Am. J. Physiol. Endocrinol. Metab. 298, E117–E126 (2010).
Google Scholar
Janssens, G. E. et al. Healthy aging and muscle function are positively associated with NAD+ abundance in humans. Nat. Aging 2, 254–263 (2022).
Google Scholar
Benyó, Z. et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid–induced flushing. J. Clin. Invest. 115, 3634–3640 (2005).
Google Scholar
Poynten, A. M. et al. Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 52, 699–704 (2003).
Google Scholar
Chedere, A., Mishra, M., Kulkarni, O., Sriraman, S. & Chandra, N. Personalized quantitative models of NAD metabolism in hepatocellular carcinoma identify a subgroup with poor prognosis. Front. Oncol. 12, 954512 (2022).
Google Scholar
Remie, C. M. E. et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. Am. J. Clin. Nutr. 112, 413–426 (2020).
Google Scholar
Moore, M. P. & Mucinski, J. M. Impact of nicotinamide riboside supplementation on skeletal muscle mitochondria and whole-body glucose homeostasis: challenging the current hypothesis. J. Physiol. 598, 3327–3328 (2020).
Google Scholar
Bird, J. G. et al. Highly efficient 5’ capping of mitochondrial RNA with NAD+ and NADH by yeast and human mitochondrial RNA polymerase. eLife 7, e42179 (2018).
Google Scholar
Grudzien-Nogalska, E., Bird, J. G., Nickels, B. E. & Kiledjian, M. NAD-capQ’ detection and quantitation of NAD caps. RNA 24, 1418–1425 (2018).
Google Scholar
Wolfram-Schauerte, M. & Höfer, K. NAD-capped RNAs – a redox cofactor meets RNA. Trends Biochem. Sci. 48, 142–155 (2023).
Google Scholar
Melkonian, E. A. & Schury, M. P. Biochemistry, anaerobic glycolysis. In StatPearls (StatPearls Publishing, Treasure Island, FL, 2025).
Luengo, A. et al. Increased demand for NAD+ relative to ATP drives aerobic glycolysis. Mol. Cell 81, 691–707.e6 (2021).
Google Scholar
Cha, Y. et al. Metabolic control of primed human pluripotent stem cell fate and function by the miR-200c-SIRT2 axis. Nat. Cell Biol. 19, 445–456 (2017).
Google Scholar
Ma, R. et al. SIRT3 suppression resulting from the enhanced β-catenin signaling drives glycolysis and promotes hypoxia-induced cell growth in hepatocellular carcinoma cells. Cell Cycle 23, 435–447 (2024).
Google Scholar
Finley, L. W. S. et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell 19, 416–428 (2011).
Google Scholar
Guo, J. et al. The role of NAD-dependent deacetylase sirtuin-2 in liver metabolic stress through regulating pyruvate kinase M2 ubiquitination. J. Transl. Med. 22, 656 (2024).
Google Scholar
Nishida, Y. et al. SIRT5 Regulates both Cytosolic and Mitochondrial Protein Malonylation with Glycolysis as a Major Target. Mol Cell 59, 321–332 (2015).
Google Scholar
Yang, L. et al. Serine catabolism feeds NADH when respiration is impaired. Cell Metab. 31, 809–821.e6 (2020).
Google Scholar
Khan, N. A. et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol. Med. 6, 721–731 (2014).
Google Scholar
Myakala, K. et al. NAD metabolism modulates inflammation and mitochondria function in diabetic kidney disease. J. Biol. Chem. 299, 104975 (2023).
Google Scholar
de Castro, J. M., Stein, D. J., Medeiros, H. R., de Oliveira, C. & Torres, I. L. S. Nicotinamide riboside neutralizes hypothalamic inflammation and increases weight loss without altering muscle mass in obese rats under calorie restriction: a preliminary investigation. Front. Nutr. 8, 648893 (2021).
Google Scholar
Kim, M.-B. et al. Nicotinamide riboside supplementation exerts an anti-obesity effect and prevents inflammation and fibrosis in white adipose tissue of female diet-induced obesity mice. J. Nutr. Biochem. 107, 109058 (2022).
Google Scholar
Wang, L., Chen, C., Zhou, H., Tao, L. & Xu, E. Nicotinamide riboside-driven modulation of SIRT3/mtROS/JNK signaling pathways alleviates myocardial ischemia-reperfusion injury. Int. J. Med. Sci. 21, 2139–2148 (2024).
Google Scholar
Abdellatif, M. et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction. Sci. Transl. Med. 13, eabd7064 (2021).
Google Scholar
Xiong, X. et al. NAD+-boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer’s disease via ATF4-dependent mitochondrial UPR. Cell Death Dis. 15, 744 (2024).
Google Scholar
Hasegawa, K., Sakamaki, Y., Tamaki, M. & Wakino, S. Nicotinamide mononucleotide ameliorates adriamycin-induced renal damage by epigenetically suppressing the NMN/NAD consumers mediated by Twist2. Sci. Rep. 12, 13712 (2022).
Google Scholar
Chandrasekaran, K. et al. NAD+ precursors repair mitochondrial function in diabetes and prevent experimental diabetic neuropathy. Int. J. Mol. Sci. 23, 4887 (2022).
Google Scholar
Fang, E. F. et al. NAD+ augmentation restores mitophagy and limits accelerated aging in Werner syndrome. Nat. Commun. 10, 5284 (2019).
Google Scholar
de Zélicourt, A. et al. CD38-NADase is a new major contributor to Duchenne muscular dystrophic phenotype. EMBO Mol. Med. 14, e12860 (2022).
Google Scholar
Gong, M. et al. Trigonelline inhibits tubular epithelial-mesenchymal transformation in diabetic kidney disease via targeting Smad7. Biomed. Pharmacother. 168, 115747 (2023).
Google Scholar
Faivre, A. et al. Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease. Nephrol. Dial. Transpl. 36, 60–68 (2021).
Google Scholar
Dollerup, O. L. et al. Effects of nicotinamide riboside on endocrine pancreatic function and incretin hormones in nondiabetic men with obesity. J. Clin. Endocrinol. Metab. 104, 5703–5714 (2019).
Google Scholar
Norheim, K. L. et al. Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial. Nat. Aging 4, 1772–1781 (2024).
Google Scholar
Simic, P. et al. Nicotinamide riboside with pterostilbene (NRPT) increases NAD+ in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI. BMC Nephrol. 21, 342 (2020).
Google Scholar
Dellinger, R. W. et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech. Dis. 3, 17 (2017).
Google Scholar
van Dijk, A. E. et al. Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance. Diab. Care 32, 1023–1025 (2009).
Google Scholar
link
